Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, inactivated bordetella pertussis, hepatitis b surface antigen (rdna), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; diphtheria - vaccines - quintanrix is indicated for primary immunisation of infants (during the first year of life) against diphtheria, tetanus, pertussis, hepatitis b and invasive disease caused by haemophilus influenzae type b and for booster immunisation of young children during the second year of life.the use of quintanrix should be determined on the basis of official recommendations.

Euroopan unioni - englanti - EMA (European Medicines Agency)

smithkline beecham ltd - rosiglitazone, glimepiride - diabetes mellitus, type 2 - drugs used in diabetes - avaglim is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - albendazole - tablets - albendazole 400 mg - albendazole - albendazole - albendazole is indicated for the treatment of the following systemic helminth diseases: * echinococcosis (hydatid disease)albendazole is indicated for the treatment of liver, lung and peritoneal cysts. experience with bone cysts and those in the central nervous system and heart is limited. * cystic echinococcosis (caused by echinococcus granulosus)albendazole is used in patients with cystic echinococcosis:1. when surgical intervention is not feasible .2. as a co-adjunct to surgical treatment. 3. prior to surgical intervention. 4. if preoperative treatment was too short, if spillage has occurred or if viable cysts were found at surgery. 5. following percutaneous drainage of cysts for diagnostic or therapeutic reasons. * alveolar echinococcosis (caused by echinococcus multilocularis)although its efficacy has not been completely demonstrated in clinical trials, albendazole is used in patients with alveolar echinococcosis in the following situations:1. in inoperable disease, particularly in cases of local or distant metastasis.2. following palliative surgery.3. following radical surgery or liver transplantation.

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - powder for inhalation - salbutamol as sulfate 200 mcg/dose - salbutamol - salbutamol - relief of bronchospasm in broncial asthma of all types, chronic, bronchitis and emphysema.

Euroopan unioni - englanti - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - avandamet is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

Euroopan unioni - englanti - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone - diabetes mellitus, type 2 - drugs used in diabetes - rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:as monotherapy-in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intoleranceas dual oral therapy in combination with-metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin-a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylureaas triple oral therapy in combination with-metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy (see section 4.4).

Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - whole virion, inactivated, containing antigen*: a/vietnam/1194/2004 (h5n1)* produced in eggs - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b and poliomyelitis.

Euroopan unioni - englanti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, hepatitis b surface antigen, bordetella pertussis (inactivated), tetanus toxoid - hepatitis b; tetanus; immunization; whooping cough; diphtheria - vaccines - tritanrix hepb is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis b (hbv) in infants from six weeks onwards (see section 4.2).

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - tablets - lamivudine 100 mg - lamivudine - lamivudine - zeffix is indicated for the treatment of chronic hepatitis b associated with the evidence of hepatitis b viral (hbv) replication and active liver inflammation in adults and also in children and adolescents aged 2 to 17 years old.